微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 13.29% | -31.67% | 9.85% | 145/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 12.1% | -48.98% | -5.24% | 145/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 12.77% | -43.24% | -18.56% | 145/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 15.68% | -17.68% | -19.4% | 144/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2024-09-30 | 19.45% | 4.92% | -17.97% | 138/159 | 22.43% | 海创药业 | 99.57% | 行业排名> |
| 2024-06-30 | 23.71% | 41.94% | 5.4% | 132/159 | 32.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-03-31 | 22.5% | 47.46% | 18.12% | 131/159 | 51.47% | 艾力斯 | 96.74% | 行业排名> |
| 2023-12-31 | 19.05% | 24.72% | 2.72% | 140/159 | 51.31% | 首药控股 | 98.96% | 行业排名> |
| 2023-09-30 | 18.54% | 10.54% | 10.98% | 138/159 | 32.31% | 迪哲医药 | 97.73% | 行业排名> |
| 2023-06-30 | 16.71% | -8.71% | 9.51% | 138/159 | 38.22% | 百利天恒 | 97.99% | 行业排名> |
| 2023-03-31 | 15.26% | -28.59% | -0.09% | 135/159 | 52.66% | 百利天恒 | 98.92% | 行业排名> |
| 2022-12-31 | 15.27% | -6.24% | -8.96% | 144/159 | 53.51% | 迈威生物 | 98.93% | 行业排名> |
| 2022-09-30 | 16.77% | -4.6% | -8.34% | 134/159 | 5.67% | 迈威生物 | 99.59% | 行业排名> |
| 2022-06-30 | 18.3% | 1.3% | -14.34% | 139/159 | 20.91% | 迈威生物 | 99.8% | 行业排名> |
| 2022-03-31 | 21.36% | -8.7% | 31.17% | 129/159 | 54.06% | 迈威生物 | 99.46% | 行业排名> |
| 2021-12-31 | 16.29% | -29.5% | -7.37% | 143/159 | 54.9% | 迈威生物 | 99.75% | 行业排名> |
| 2021-09-30 | 17.58% | -20.15% | -2.67% | 126/159 | 46.49% | 迈威生物 | 99.67% | 行业排名> |
| 2021-06-30 | 18.07% | -25.18% | -22.8% | 135/159 | 46.97% | 迈威生物 | 99.44% | 行业排名> |
| 2021-03-31 | 23.4% | -0.18% | 1.29% | 113/159 | 53.79% | 迈威生物 | 98.57% | 行业排名> |
| 2020-12-31 | 23.1% | 15.18% | 4.91% | 131/159 | -147.51% | 首药控股 | 99.93% | 行业排名> |
| 2020-09-30 | 22.02% | 9.43% | -8.81% | 109/159 | 56.06% | 艾力斯 | 99.41% | 行业排名> |
| 2020-06-30 | 24.15% | 19.92% | 3.01% | 117/159 | 53.85% | 艾力斯 | 98.7% | 行业排名> |
| 2020-03-31 | 23.44% | 18.29% | 16.88% | 101/159 | 54.83% | 艾力斯 | 99.4% | 行业排名> |
| 2019-12-31 | 20.06% | -11.12% | -0.33% | 129/159 | -1232.76% | 首药控股 | 99.94% | 行业排名> |
| 2019-09-30 | 20.12% | -15.24% | -0.06% | 101/159 | 54.86% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-06-30 | 20.14% | -10.95% | 1.61% | 108/159 | 54.88% | 微芯生物 | 95.14% | 行业排名> |
| 2019-03-31 | 19.82% | -21.86% | -12.18% | 100/159 | 50.75% | 多瑞医药 | 95.59% | 行业排名> |
| 2018-12-31 | 22.57% | -4.51% | -4.95% | 124/159 | -210.26% | 微芯生物 | 95.81% | 行业排名> |
| 2018-09-30 | 23.74% | 3.23% | 4.99% | 96/159 | 53.75% | 微芯生物 | 96.09% | 行业排名> |
| 2018-06-30 | 22.61% | -8.29% | -10.84% | 100/159 | 53.16% | 微芯生物 | 96.11% | 行业排名> |
| 2018-03-31 | 25.36% | -2.95% | 7.32% | 93/159 | 53.78% | 微芯生物 | 95.5% | 行业排名> |
| 2017-12-31 | 23.63% | -2.34% | 2.76% | 112/159 | 52.25% | 微芯生物 | 96.27% | 行业排名> |
| 2017-09-30 | 23% | -0.19% | -6.73% | 90/159 | 48.76% | 贝达药业 | 95.47% | 行业排名> |
| 2017-06-30 | 24.66% | 5.26% | -5.65% | 92/159 | 47.61% | 贝达药业 | 95.51% | 行业排名> |
| 2017-03-31 | 26.13% | 15.46% | 7.99% | 74/159 | 46.62% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 24.2% | 11.84% | 5.03% | 100/159 | 48.17% | 贝达药业 | 95.74% | 行业排名> |
| 2016-09-30 | 23.04% | 6.87% | -1.64% | 73/159 | 45.83% | 退市金泰 | 96.19% | 行业排名> |
| 2016-06-30 | 23.42% | 7.82% | 3.5% | 81/159 | 45.93% | 贝达药业 | 95.81% | 行业排名> |
| 2016-03-31 | 22.63% | 2.6% | 4.6% | 69/159 | 43.86% | 退市金泰 | 95.93% | 行业排名> |